About Illumina, Inc. (ILMN)

Company Description:

Illumina, Inc. specializes in the development, manufacturing, and marketing of life science tools and integrated systems for the analysis of genetic variation and function. The company's primary focus is on sequencing and array-based solutions for genetic and genomic analysis.

Founded in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee, Illumina is headquartered in San Diego, California. The company has revolutionized genetic sequencing with its innovative technologies, making genetic analysis more accessible and affordable.

Main Product(s):

Illumina's main products include sequencing and array-based solutions for genetic analysis, which are used in various fields such as genomics, pharmaceuticals, and clinical laboratory environments.

Short History of Illumina, Inc:

• April 1998 – Illumina was founded by a team of scientists and entrepreneurs.
• July 2000 – The company went public on the NASDAQ.
• 2010s – Illumina became a dominant player in the DNA sequencing market.
• 2014 – Launched HiSeq X Ten Sequencing System, which significantly reduced the cost of sequencing a human genome.
• 2017 – Acquired GRAIL, a healthcare company focused on cancer detection.
• 2021 – Announced the launch of the NovaSeq X Series, advancing genomic sequencing capabilities.